Maria Aránzazu A. A.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 1 Evaluation of GSK2857916 Combined with Standard of Care in Newly Diagnosed Multiple Myeloma Patients
- Safety and Tolerability Assessment of Odronextamab and Cemiplimab in Adult Patients with B-Cell Non-Hodgkin’s Lymphoma
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
Data & Insights
Has run more than one trial at 184 of 361 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of blood cancers, with particular emphasis on multiple myeloma and lymphoid malignancies. Their research encompasses both newly diagnosed cases and relapsed/refractory conditions.
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Multiple Myeloma
Treatment approaches focus on innovative therapeutic combinations and targeted immunotherapies.
Autoimmune Blood Disorders
The investigator conducts research in autoimmune hematologic conditions, focusing on novel therapeutic approaches for various immune-mediated blood disorders.
- Immune Thrombocytopenia
- Warm Autoimmune Hemolytic Anemia
- Hypereosinophilic Syndrome
Research emphasizes immunoglobulin therapies and targeted biological treatments.
Myeloproliferative Disorders
The investigator studies chronic blood disorders with a focus on myelofibrosis and related conditions.
- JAK Inhibitor Therapy
- Novel Combination Approaches
- Advanced Malignancies
Treatment strategies include targeted molecular therapies and innovative drug combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.